Phenotypic, genotypic, and functional characterization of normal and acute myeloid leukemia-derived marrow endothelial cells.

[1]  S. Leem,et al.  Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. , 2015, Cancer research.

[2]  S. Rafii,et al.  Activation of the vascular niche supports leukemic progression and resistance to chemotherapy. , 2014, Experimental hematology.

[3]  D. Scadden,et al.  Cellular thrust and parry in the leukemic niche. , 2014, Blood.

[4]  B. Leber,et al.  Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs , 2014, The Journal of experimental medicine.

[5]  T. Enver,et al.  Leukemia propagating cells rebuild an evolving niche in response to therapy. , 2014, Cancer cell.

[6]  R. Davis,et al.  Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. , 2014, Blood.

[7]  E. Scott,et al.  Functional Integration of Acute Myeloid Leukemia into the Vascular Niche , 2014, Leukemia.

[8]  J. Lorens,et al.  In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells , 2014, Leukemia research and treatment.

[9]  F. Marincola,et al.  Leukemia cells induce changes in human bone marrow stromal cells , 2013, Journal of Translational Medicine.

[10]  A. Arbab,et al.  Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis : studies in mice with K/BxN serum-induced arthritis. , 2013, Arthritis and rheumatism.

[11]  M. Kuroda,et al.  Leukemia cell to endothelial cell communication via exosomal miRNAs , 2013, Oncogene.

[12]  Ø. Bruserud,et al.  Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells , 2013 .

[13]  Ø. Bruserud,et al.  Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells , 2013, Oncotarget.

[14]  H. Urlaub,et al.  β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. , 2013, Blood.

[15]  G. Madlambayan,et al.  Leukemia Mediated Endothelial Cell Activation Modulates Leukemia Cell Susceptibility to Chemotherapy through a Positive Feedback Loop Mechanism , 2013, PloS one.

[16]  N. Heisterkamp,et al.  Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. , 2013, Blood.

[17]  Jingru Zhang,et al.  Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. , 2013, Carcinogenesis.

[18]  David G Hendrickson,et al.  Differential analysis of gene regulation at transcript resolution with RNA-seq , 2012, Nature Biotechnology.

[19]  T. Suda,et al.  Two anatomically distinct niches regulate stem cell activity. , 2012, Blood.

[20]  A. Reinisch,et al.  Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. , 2012, Blood.

[21]  S. Rafii,et al.  Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent , 2012, Leukemia.

[22]  A. Zarbock,et al.  Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation , 2011, Journal of Molecular Medicine.

[23]  Ulrich Keilholz,et al.  Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. , 2011, Blood.

[24]  C. Cogle,et al.  Angiogenesis in Acute Myeloid Leukemia and Opportunities for Novel Therapies , 2011, Journal of oncology.

[25]  F. Gao,et al.  CD44 mediates oligosaccharides of hyaluronan-induced proliferation, tube formation and signal transduction in endothelial cells , 2011, Experimental biology and medicine.

[26]  E. Scott,et al.  Leukemia regression by vascular disruption and antiangiogenic therapy. , 2010, Blood.

[27]  Ø. Bruserud,et al.  Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release , 2010, Expert opinion on investigational drugs.

[28]  D. Ribatti,et al.  Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma , 2009, Clinical Cancer Research.

[29]  D. Scadden,et al.  The leukemic stem cell niche: current concepts and therapeutic opportunities. , 2009, Blood.

[30]  E. Estey,et al.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. , 2009, Blood.

[31]  Sören Lehmann,et al.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.

[32]  Ø. Bruserud,et al.  Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators , 2009, British journal of haematology.

[33]  Angela C. Colmone,et al.  Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells , 2008, Science.

[34]  Ø. Bruserud,et al.  Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels , 2008, Leukemia.

[35]  J. Liesveld,et al.  Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. , 2007, Leukemia research.

[36]  K. Parmar,et al.  Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia , 2007, Proceedings of the National Academy of Sciences.

[37]  W. Berdel,et al.  Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity , 2007, Leukemia.

[38]  W. Berdel,et al.  Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. , 2006, Haematologica.

[39]  S. Sallan,et al.  Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. , 2006, Experimental hematology.

[40]  J. Lancet,et al.  Acute myelogenous leukemia—microenvironment interactions: Role of endothelial cells and proteasome inhibition , 2005, Hematology.

[41]  P. Smolewski,et al.  Circulating endothelial cells in patients with acute myeloid leukemia , 2005, European journal of haematology.

[42]  Dan Mercola,et al.  Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. , 2005, Cancer research.

[43]  Ø. Bruserud,et al.  Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels , 2005, European journal of haematology.

[44]  F. Appelbaum,et al.  Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). , 2001, Experimental hematology.

[45]  M. Schapira,et al.  Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. , 2001, Blood.

[46]  S. Rafii,et al.  Regulation of hematopoiesis by microvascular endothelium. , 1997, Leukemia & lymphoma.

[47]  S. Ergün,et al.  Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. , 1997, Blood.

[48]  B. Zetter,et al.  In situ labelling of vascular endothelium with fluorescent acetylated low density lipoprotein , 1985, The Histochemical Journal.

[49]  T. Suda,et al.  EFFECT OF HYDROCORTISONE ON LONG‐TERM HUMAN MARROW CULTURES , 1981, British journal of haematology.

[50]  E. Edelman,et al.  Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. , 2006, Blood.

[51]  George M. Rodgers,et al.  Evidence of increased angiogenesis in patients with acute myeloid leukemia. , 2000, Blood.

[52]  M. Adolphe,et al.  A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes. , 1995, Journal of immunological methods.

[53]  S. Rafii,et al.  Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. , 1994, Blood.